Redefining the druggable landscape.

EMP™ TECHNOLOGY

DISCOVERY ENABLED

OUR MISSION:

Unlock the full therapeutic potential of membrane protein targets to create transformative options for future patients

  • Granting access to medically important targets among the hundreds that are currently considered ‘intractable’ or ‘undruggable’
  • Providing the unparalleled opportunity to directly use purified proteins for discovery processes
  • Removing multi-span membrane protein (MMP)-specific limitations in many discovery approaches, thereby boosting the probability to develop drugs that would otherwise remain elusive

OUR TECHNOLOGY

The foundation of Abilita Therapeutics’ Drug Discovery capabilities is our EMP™ technology, which is based on the principles of directed evolution.

Enabled Membrane Proteins (EMPs™) are stability and expression enhanced variants that enable discovery and optimization of drug candidates.

Read More

THE MARKET FOR DRUGS TARGETING MMPs

  • ~2/3 of all FDA-approved drugs are targeting 1/6 of known MMP targets
  • Hundreds of MMPs are potential targets for life-saving therapeutics that remain unexplored
of marketed drugs target MMPs
0 %
MMP targets identified in the human genome
> 0
therapeutic antibodies approved by the FDA
2
of all MMPs are currently drugged
< 0 %

ABILITA THERAPEUTICS NEWS

NEWS, EVENTS AND OTHER INFORMATION FROM ABILITA THERAPEUTICS

Our Team

About

CONTACT

5785 Oberlin Drive, Suite 100
San Diego, California 92121, USA

  • [+1] 858-246-6778
  • info@abilitabio.com
Facebook Twitter Linkedin

PRIVACY POLICY

© Abilita Therapeutics, Inc. 2023 All Rights Reserved